Amgen Announces CFO Retirement, Appoints Former Executive Thomas Dittrich as Successor
AMGN sits 23% above its 52-week low of $267.83.
Summary
Amgen announced the planned retirement of its CFO, Peter H. Griffith, effective August 31, 2026, and the appointment of Thomas Dittrich, a former Amgen executive and experienced biopharma CFO, as his successor.
Key Events · Executive and Board Changes · AMGN
-
CFO Retirement Announced
Peter H. Griffith will retire from his role as Executive Vice President and Chief Financial Officer, effective August 31, 2026. He will remain employed in a non-executive officer position until January 31, 2027, to support a seamless transition.
-
New CFO Appointed
Thomas Dittrich will join Amgen as Executive Vice President on July 1, 2026, and will assume the role of Executive Vice President and Chief Financial Officer effective September 1, 2026. He will report directly to the Chairman and CEO.
-
Experienced Successor with Prior Amgen Tenure
Mr. Dittrich brings over 30 years of international leadership experience, including recent CFO roles at Galderma Group AG and Shire Pharmaceuticals. Notably, he previously served at Amgen for eight years (2006-2014) as Vice President, Finance Corporate Planning and Chief Accounting Officer.
-
Substantial Compensation Package
Mr. Dittrich's compensation includes an annual base salary of CHF 1,070,000, a target annual long-term incentive award of CHF 4,500,000, and one-time awards totaling CHF 14,750,000 (including RSUs, a cash bonus, and a retention bonus) to compensate for foregone equity and facilitate his relocation from Switzerland.
Analysis · AMGN · Life Sciences
The planned retirement of a Chief Financial Officer is a significant leadership transition for a company of Amgen's size. However, the impact is mitigated by the orderly transition plan and the appointment of Thomas Dittrich, who brings extensive experience as a CFO at other major biopharma companies and previously served at Amgen. This ensures continuity and strong financial leadership, aligning with a broader leadership reorganization noted in recent filings.
At the time of this filing, AMGN was trading at $330.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $178.5B. The 52-week trading range was $267.83 to $391.29. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.